Aim: To collect efficacy and safety data of enzalutamide after docetaxel, we retrospectively evaluated the Italian Named Patient Program results. Patients & methods: Two hundred and nine metastatic castration-resistant prostate cancer patients were enrolled. Median age was 73 years. Total 42.1% patients had pain, 14.4% had a performance status of two and 59.8% had a Gleason score ≥8. Total 31.1% had previously received ≥2 chemotherapies, 15.3 and 12% had been previously treated with abiraterone and cabazitaxel, respectively and 14.8% had received both. Results: Median progression-free survival and overall survival were 4.8 and 13.1 months, respectively. A prostate-specific antigen reduction ≥50% was observed in 49.1%. Total 32.7% abiraterone-pretreated patients achieved a biochemical response compared with 56% of abiraterone-naive patients. Conclusion: Enzalutamide was safe and well tolerated. Its antitumor activity in abiraterone-pretreated patients was limited.
Maines F., De Giorgi U., Procopio G., Facchini G., Fratino L., Sabbatini R., et al. (2018). Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: The Italian Named Patient Program. FUTURE ONCOLOGY, 14(26), 2691-2699 [10.2217/fon-2018-0113].
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: The Italian Named Patient Program
Massari F.;
2018
Abstract
Aim: To collect efficacy and safety data of enzalutamide after docetaxel, we retrospectively evaluated the Italian Named Patient Program results. Patients & methods: Two hundred and nine metastatic castration-resistant prostate cancer patients were enrolled. Median age was 73 years. Total 42.1% patients had pain, 14.4% had a performance status of two and 59.8% had a Gleason score ≥8. Total 31.1% had previously received ≥2 chemotherapies, 15.3 and 12% had been previously treated with abiraterone and cabazitaxel, respectively and 14.8% had received both. Results: Median progression-free survival and overall survival were 4.8 and 13.1 months, respectively. A prostate-specific antigen reduction ≥50% was observed in 49.1%. Total 32.7% abiraterone-pretreated patients achieved a biochemical response compared with 56% of abiraterone-naive patients. Conclusion: Enzalutamide was safe and well tolerated. Its antitumor activity in abiraterone-pretreated patients was limited.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
